Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Histone methyltransferase MLL4 controls myofiber identity and muscle performance through MEF2 interaction
Lin Liu, … , Kai Ge, Zhenji Gan
Lin Liu, … , Kai Ge, Zhenji Gan
Published June 16, 2020
Citation Information: J Clin Invest. 2020;130(9):4710-4725. https://doi.org/10.1172/JCI136155.
View: Text | PDF
Research Article Metabolism Muscle biology

Histone methyltransferase MLL4 controls myofiber identity and muscle performance through MEF2 interaction

  • Text
  • PDF
Abstract

Skeletal muscle depends on the precise orchestration of contractile and metabolic gene expression programs to direct fiber-type specification and to ensure muscle performance. Exactly how such fiber type–specific patterns of gene expression are established and maintained remains unclear, however. Here, we demonstrate that histone monomethyl transferase MLL4 (KMT2D), an enhancer regulator enriched in slow myofibers, plays a critical role in controlling muscle fiber identity as well as muscle performance. Skeletal muscle–specific ablation of MLL4 in mice resulted in downregulation of the slow oxidative myofiber gene program, decreased numbers of type I myofibers, and diminished mitochondrial respiration, which caused reductions in muscle fatty acid utilization and endurance capacity during exercise. Genome-wide ChIP-Seq and mRNA-Seq analyses revealed that MLL4 directly binds to enhancers and functions as a coactivator of the myocyte enhancer factor 2 (MEF2) to activate transcription of slow oxidative myofiber genes. Importantly, we also found that the MLL4 regulatory circuit is associated with muscle fiber–type remodeling in humans. Thus, our results uncover a pivotal role for MLL4 in specifying structural and metabolic identities of myofibers that govern muscle performance. These findings provide therapeutic opportunities for enhancing muscle fitness to combat a variety of metabolic and muscular diseases.

Authors

Lin Liu, Chenyun Ding, Tingting Fu, Zhenhua Feng, Ji-Eun Lee, Liwei Xiao, Zhisheng Xu, Yujing Yin, Qiqi Guo, Zongchao Sun, Wanping Sun, Yan Mao, Likun Yang, Zheng Zhou, Danxia Zhou, Leilei Xu, Zezhang Zhu, Yong Qiu, Kai Ge, Zhenji Gan

×

Figure 5

MLL4 cooperates with MEF2 to activate slow myofiber gene transcription.

Options: View larger image (or click on image) Download as PowerPoint
MLL4 cooperates with MEF2 to activate slow myofiber gene transcription.
...
(A and B) Co-IP experiments were performed by cotransfecting HA-MEF2A and Flag-MLL4 in HEK293 cells, as indicated at the top. Antibodies against the HA or Flag epitope were used for co-IP. Extracts (Input) from the HEK293 cells and proteins from the IP were analyzed by immunoblotting. Representative results for co-IP are shown. n = 3 independent experiments. (C) Co-IP results with extracts prepared from C2C12 myotubes using anti-MLL4 antibody or control IgG. Representative results are shown. n = 3 independent experiments. (D) MLL4 and MEF2D ChIP-Seq tracks from myocytes at the Myh7 locus. Two putative conserved MEF2-binding sites within the cis-proximal enhancer region of the Myh7 gene are shown. (E) MLL4 and MEF2 synergistically activate Myh7 gene promoter. The rat Myh7.Luc.3.5k promoter reporter was used in cotransfection studies in HEK293 cells in the presence of expression vectors indicated. Values represent mean (± SEM) firefly/renilla luciferase activity shown as arbitrary units (AU) normalized (=1.0) to vector control. n = 4 independent experiments. (F) Results of transient transfection performed with rMyh7.Luc.3.5k and truncation mutant of rMyh7.Luc.408 in HEK293 cells in the presence of expression vectors indicated. n = 4–5 independent experiments. (G) Left: MLL4 and MEF2D ChIP-Seq tracks from myocyte at the Myh7b locus. Right: putative conserved MEF2-binding site within the mouse Myh7b promoter regions. (H) Top: site-directed mutagenesis was used to abolish the MEF2 response element. Bottom: mMyh7b.Luc.1k (WT) or MEF2mut.mMyh7b.Luc.1k promoter reporters were used in cotransfection studies in HEK293 cells in the presence of expression vectors indicated. n = 5 independent experiments. Values are represented as mean ± SEM. *P < 0.05 vs. corresponding controls; #P < 0.05 compared with MEF2A alone. P values were determined using 1-way ANOVA coupled to a Fisher’s LSD post hoc test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts